Core Viewpoint - Company 基石药业-B (02616.HK) announced that its drug 普吉华® (Pralsetinib capsules, 100 mg) has been included in the latest National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List published by China's National Healthcare Security Administration, which will take effect on January 1, 2026 [1] Group 1 - 普吉华® is an oral targeted therapy taken once daily [1] - The drug has been approved by the National Medical Products Administration (NMPA) in China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are RET gene fusion positive, as well as for adult and pediatric patients aged 12 and above with RET mutation medullary thyroid carcinoma (MTC) requiring systemic treatment [1] - The drug is also indicated for adult and pediatric patients aged 12 and above with advanced or metastatic RET fusion positive thyroid cancer requiring systemic treatment and who are refractory to radioactive iodine treatment, if applicable [1] Group 2 - 普吉华® has already been approved in Hong Kong for the treatment of adult patients with metastatic NSCLC who are RET gene fusion positive [1] - In Taiwan, the drug has been approved for the treatment of locally advanced or metastatic RET fusion positive NSCLC, advanced or metastatic RET mutation MTC requiring systemic treatment, and advanced or metastatic RET fusion positive thyroid cancer in adults requiring systemic treatment and refractory to radioactive iodine treatment [1]
基石药业-B(02616.HK)宣布普吉华®(普拉替尼胶囊)纳入2025年国家医保目录